Gore Introduces Excluder TAMBE Device in Europe

April 22, 2026—Gore & Associates announced that its Excluder thoracoabdominal branch endoprosthesis (TAMBE) received CE Mark approval earlier this year and is being introduced in hospitals across Europe.

Study Highlights Insurance-Based Disparities in TEVAR for TBAD

April 21, 2026—In this retrospective analysis, Zil-E-Ali et al found that patients with government-funded insurance who underwent urgent or emergent thoracic endovascular aortic repair (TEVAR) for type B aortic dissection (TBAD) presented with more advanced disease and experienced significantly higher short- and long-term mortality than commercially insured patients.

Shape Memory Medical Initiates First-in-Human FLAGSHIP Study of False Lumen Embolization System

April 1, 2026—Shape Memory Medical has announced the first patient enrollments in the FLAGSHIP study, a prospective single-arm open-label first-in-human trial evaluating its investigational False Lumen Embolization (FLE) System for treatment of aortic dissection.

SVS Updates Guidelines for Blunt Thoracic Aortic Injury

March 24, 2026—The Society for Vascular Surgery (SVS) announced the release of an updated clinical practice guideline on the management of blunt thoracic aortic injury (BTAI).

Gore Excluder TAMBE Introduced in Japan

December 19, 2025—Gore & Associates G.K. in Minato-ku, Tokyo, Japan, announced the first clinical use in Japan of the Gore Excluder thoracoabdominal branch endoprosthesis (TAMBE).

ARISE III Trial of Gore Ascending Stent Graft Begins Enrollment

December 15, 2025—Gore & Associates announced the first implantation of its investigational Gore Ascending Stent Graft in the ARISE III trial for the treatment of an acute type A dissection.

Philips Expands Commercial Availability of LumiGuide Light-Based 3D Navigation Solution 

December 1, 2025—Royal Philips announced the expanded commercial availability of its LumiGuide device guidance across Europe and the United States.

RapidAI’s Rapid Aortic Solution Cleared by FDA 

November 18, 2025—RapidAI announced FDA clearance of Aortic Management, part of the company’s Rapid Aortic product, a clinical artificial intelligence (AI) solution for acute assessment and longitudinal management of aortic disease.

Terumo Aortic’s Thoraflex Hybrid Device for Complex Aortic Arch Procedures to Be Covered Under New MS-DRG

September 18, 2025—Terumo Aortic announced that a new Medicare Severity Diagnosis-Related Group (MS-DRG) for complex aortic arch procedures has been established by the Centers for Medicare & Medicaid Services (CMS) that will take effect on October 1, 2025.

Vivasure PerQseal Elite Approved for Venous Indication in Europe

June 24, 2025—Vivasure Medical announced that it has received European CE Mark approval for an expanded indication for its fully bioresorbable, sutureless PerQseal Elite vascular closure system to include large-bore venous closure.

Gore TAG TBE Approved for Zones 0 and 1 Aortic Arch Repair

June 23, 2025—Gore & Associates announced that the company’s TAG thoracic branch endoprosthesis (TBE) has received FDA approval for use in zones 0 and 1, expanding its indication for the endovascular repair of lesions in the aortic arch and descending thoracic aorta while preserving flow to a single aortic arch branch vessel.

FDA Approves New Large-Diameter Tapered Designs of Gore TAG Conformable Thoracic Stent Graft

April 3, 2025—Gore & Associates recently announced an expansion of the Gore TAG conformable thoracic stent graft with Active Control system product line after FDA approval of four new large-diameter tapered designs: 34 x 28 mm, 37 x 31 mm, 40 x 34 mm, and 45 x 37 mm.

Cook’s Zenith Alpha 2 Thoracic Endovascular Graft Launched in the United States

March 3, 2025—Cook Medical announced that the Zenith Alpha 2 (ZTA2) thoracic endovascular graft is commercially available in the United States.

Biotronik Partners With Egg Medical to Market EggNest Radiation Protection Systems

February 19, 2025—Biotronik announced it is partnering with Egg Medical, Inc. to cosell Egg Medical’s EggNest radiation protection systems for health care workers in the United States.

Study Examines Nationwide Trends in Aortic Aneurysm Admissions and Repairs

January 31, 2025—In a multicenter, retrospective review of patients admitted with intact and ruptured abdominal aortic aneurysms (AAAs), thoracic aortic aneurysms (TAAs), and thoracoabdominal aortic aneurysms (TAAAs), Conroy et al found that use of endovascular and complex endovascular techniques increased over the past 2 decades, surpassing open repair, and both intact AAA repairs and ruptured AAA admissions significantly decreased.

Artivion AMDS Evaluated in PERSEVERE Trial

January 27, 2025—Artivion, Inc. announced the presentation of clinical data from the PERSEVERE United States investigational device exemption (IDE) trial of the company’s AMDS hybrid prosthesis.

Study Finds Mortality and Rupture Are Uncommon After Elective FB-EVAR of Asymptomatic, Intact Thoracoabdominal Aortic Aneurysms

December 9, 2024—In a multicenter, prospective, nonrandomized study evaluating outcomes of fenestrated-branched endovascular aortic repair (FB-EVAR) in patients with asymptomatic, intact thoracoabdominal aortic aneurysms (TAAAs), Oderich et al found that the procedure was effective out to 5 years, with a low incidence of early and late aortic-related mortality (ARM) and aortic rupture.

Artivion Granted FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis

December 9, 2024—Artivion, Inc. announced that the FDA has granted a humanitarian device exemption (HDE) for the use of the AMDS hybrid prosthesis (formerly known as the Ascyrus Medical dissection stent), an aortic arch remodeling device for in acute DeBakey type I dissections in the presence of malperfusion.

Centerline Biomedical’s IOPS Guidewire Handle Receives FDA Clearance

December 4, 2024—Centerline Biomedical, Inc. announced that the company received FDA 510(k) clearance for its IOPS intra-operative positioning system guidewire handle.

SVS Launches Highway to Health Public Awareness Campaign

October 23, 2024—The Society for Vascular Surgery (SVS) announced the launch of its Highway to Health campaign aims to educate and raise awareness about the symptoms and risk factors associated with vascular disease.